Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Phase III study showed that MF59 adjuvanted influenza vaccine, Fluad, was highly efficacious in protecting infants and young children against seasonal influenza and met its primary endpoint.
Subscribe to our email newsletter
The Phase III randomised, blinded, controlled study was conducted at trial sites in Germany and Finland.
Novartis said that the study aimed to assess the reactogenicity of the MF59 adjuvanted influenza vaccine compared with non-adjuvanted influenza vaccines, and the protective efficacy of the MF59 adjuvanted vaccine against confirmed influenza illness compared with non-adjuvanted influenza vaccine and non-influenza control vaccines.
Reportedly, the results also showed that MF59 adjuvanted vaccine has an acceptable tolerability profile, similar to the non-adjuvanted influenza vaccines used in the study.
Novartis Vaccines and Diagnostics division head Andrin Oswald said that Novartis is committed to developing vaccine technologies to combat the threat of seasonal and pandemic influenza.